Expert Perspectives on the Role of Traditional Versus Emerging Therapies in Multiple Myeloma : Episode 1
Expert Perspectives on the Role of Traditional Versus Emerging Therapies in Multiple Myeloma
A video preview for an upcoming expert panelist discussion of recent updates in the multiple myeloma treatment landscape.
Now Viewing
EP: 1.Expert Perspectives on the Role of Traditional Versus Emerging Therapies in Multiple Myeloma
EP: 2.The Evolving Treatment Landscape of Transplant-Eligible Newly Diagnosed Multiple Myeloma
EP: 3.Should Every Patient With Newly Diagnosed MM Receive a Transplant?
EP: 4.Selecting The Appropriate Treatment in Transplant-Eligible Newly Diagnosed MM
EP: 5.Approaching Induction Therapy for Patients With Transplant-Ineligible MM
EP: 6.Choosing the Right Treatment for Patients With Transplant Ineligible MM
EP: 7.Selecting Treatment Regimens for Multiple Myeloma at First Relapse
EP: 8.BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
EP: 9.Non–BCMA-Targeting Bispecific Antibodies in R/R MM
EP: 10.R/R MM: Optimizing Treatment Sequencing With Bispecific Antibodies
EP: 11.What is the Role of CAR T-Cell Therapy in R/R MM?
EP: 12.Unmet Needs and Future Directions in Care in Multiple Myeloma
EP: 13.Recap: MRD Negativity, Frailty, and Emerging Therapies in Multiple Myeloma
Related Videos
Related Content
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Article
Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Article
Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
